? ?Dibucaine Hydrochloride (CAS 61-12-1) | High-Purity Local Anesthetic & Sodium Channel Inhibitor? ?

?? ?Product Overview?

?Dibucaine Hydrochloride? (CAS 61-12-1), also known as ?Cinchocaine HCl?, is a potent ?amide-type local anesthetic? and ?sodium channel blocker? with the molecular formula ?C??H??N?O?·HCl? and a molecular weight of ?379.92?. This white crystalline powder (purity ≥99%) is widely used for its rapid-acting nerve-blocking properties, offering effective pain relief in clinical and research settings. It exhibits strong lipid solubility, enabling deep tissue penetration and prolonged anesthetic effects.

?Key Functions?:

• Induces local anesthesia for surgical and diagnostic procedures.

• Inhibits voltage-gated sodium channels in neurophysiological studies.

• Serves as a pharmaceutical intermediate or reference standard.

?Target Industries?: Pharmaceutical manufacturing, biomedical research, and clinical applications.

? ?Key Advantages?

?? ?Applications?

• ?Surgical Anesthesia?: Topical or injectable formulations for minor procedures.

• ?Neurological Research?: Sodium channel inhibition studies in cellular models.

• ?Pain Management?: Relief for acute or chronic neuropathic pain.

?? ?Quality Assurance?

• ?Testing Standards?: Validated via ?HPLC, NMR?, and ?FTIR? spectroscopy.?

• Packaging?: Available in ?1g–25kg? customizable batches (aluminum foil bags or bulk drums).

• ?Storage?: Sealed in dry, cool conditions to maintain integrity.

?? ?Market Insights?

The global local anesthetics market is projected to grow at ?5.8% CAGR (2025–2030)?, driven by rising demand for non-opioid pain management solutions. Dibucaine remains critical in niche neurological research, with ?Asia-Pacific? emerging as a key production hub due to cost-efficient synthesis and advanced R&D infrastructure.